Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cellular Therapy

DLI after haploidentical BMT with post-transplant CY

Bone Marrow Transplantation volume 50, pages 56–61 (2015)Cite this article

Subjects

Abstract

Forty-two patients relapsing after an unmanipulated haploidentical BM transplant and post-transplant CY (PT-CY), were given 108 DLI, with median interval from transplant of 266 days (range, 67–1372). DLI were given at escalating doses, expressed as CD3+ cells/kg, without GVHD prophylaxis, and ranged from 1 × 103 to 1 × 107 cells/kg (median 5 × 105 cells/kg). The average number of DLI per patient was 2.6 (range, 1–6). The diagnosis was leukemias (n=32) grafted with a myeloablative regimen and Hodgkin’s disease (n=10), grafted with a nonmyeloablative regimen. Leukemic patients with molecular relapse (n=20), received DLI alone (n=17) or in association with azacytidine (n=3); leukemic patients with hematologic relapse (n=12) received chemotherapy followed by DLI (n=11) or DLI alone (n=1); Hodgkin patients received DLI following 1–3 courses of chemotherapy. In these three groups the incidence of acute GVHD II–III was 15%, 17% and 10%; response rate was 45%, 33% and 70%; 2-year actuarial survival was 43%, 19% and 80% respectively. This study confirms that escalating doses of DLI can be given in the haploidentical setting with PT-CY, with a relatively low risk of acute GVHD. Response rates and survival are dependent on the underlying disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  2. Bortin MM, Rimm AA, Saltzstein EC . Graft versus leukemia: quantification of adoptive immunotherapy in murine leukemia. Science 1973; 179: 811–813.

    Article  CAS  PubMed  Google Scholar 

  3. Tomblyn M, Lazarus HM . Donor lymphocyte infusions. The long and winding road: how should it be traveled? Bone Marrow Transplant 2008; 42: 569–579.

    Article  CAS  PubMed  Google Scholar 

  4. De Lima M, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft versus- host disease. Bone Marrow Transplant 2001; 27: 73B.

    Article  Google Scholar 

  5. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  6. Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lint MT, Gualandi F et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 927–932.

    Article  CAS  PubMed  Google Scholar 

  7. Mackinnon S, Papadopoulos E, Carabasi M, Reich L, Collins N, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    CAS  PubMed  Google Scholar 

  8. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895–902.

    Article  CAS  PubMed  Google Scholar 

  9. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S et al. Full-haplotype mismatched hematopoietic stem cell transplantation: a phase II study in patients with acute leukemia at high risk or relapse. J Clin Oncol 2005; 23: 3447–3454.

    Article  PubMed  Google Scholar 

  10. Kolb HJ, Günther W, Schumm M, Holler E, Wilmanns W, Thierfelder S . Adoptive immunotherapy in canine chimeras. Transplantation 1997; 63: 430–436.

    Article  CAS  PubMed  Google Scholar 

  11. Huang Xiao-Jun, Liu Dai-Hong, Liu Kai-Yan, Xu Lan-Ping, Chen Huan, Han Wei . Donor lymphocyte infusion for the treatment of leukemia relapse after HLA mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414–417.

    Article  PubMed  Google Scholar 

  12. Yan C-H, Liu D-H, Xu L-P, Liu K-Y, Zhao T, Wang Y et al. Modified donor lymphocyte infusion associated acute graft-versus-host disease after haploidentical T-cell replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant 2012; 26: 868–876.

    Article  PubMed  Google Scholar 

  13. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F et al. Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning. Biol Blood Marrow Transplant 2013; 19: 117–122.

    Article  CAS  PubMed  Google Scholar 

  14. Raiola A, Dominietto A, Varaldo R, Ghiso A, Galaverna F, Bramanti S et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplant 2013; 49: 190–194.

    Article  PubMed  Google Scholar 

  15. Pozzi S, Geroldi S, Tedone E, Luchetti S, Grasso R, Colombo N et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013; 160: 503–509.

    Article  PubMed  Google Scholar 

  16. Bar M, Sandmaier BM, Inamoto Y, Bruno B, Hari P, Chauncey T et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant 2013; 19: 949–957.

    Article  PubMed  Google Scholar 

  17. Raiola AM, Van Lint MT, Valbonesi M, Lamparelli T, Gualandi F, Occhini D et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003; 31: 687–693.

    Article  CAS  PubMed  Google Scholar 

  18. Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K et al. HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 2013; 20: 314–318.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 2004; 34: 511–514.

    Article  CAS  PubMed  Google Scholar 

  20. De Rosa G, Pezzullo L, Scarpato N, Selleri C, Lucania A, Rotoli B. Donor lymphocyte infusion for post-transplant relapse of Hodgkin’s lymphoma. Haematologica 2000; 85: 780–781.

    CAS  PubMed  Google Scholar 

  21. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Non myeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006; 12: 172–183.

    Article  PubMed  Google Scholar 

  22. Chang Y-J, Huang X-J . Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom? Blood Reviews 2013; 27: 55–62.

    Article  CAS  PubMed  Google Scholar 

  23. Porter David L, Alyea Edwin P, Antin Joseph H, DeLima Marcos, Eli Estey JH, Falkenburg Frederik et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010; 16: 1467–1503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Schmid C, Labopin M, Nagler A, Bornhauser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938–4945.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partly supported by the ‘Associazione Italiana Ricerca contro il Cancro’ Milano, Fondi Finalizzati, Ministero Salute, Italia, FARITMO Genova and CARIGE Genova, Italy.

Author information

Authors and Affiliations

  1. Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy

    A Ghiso, A M Raiola, F Gualandi, A Dominietto, R Varaldo, M T Van Lint, S Bregante, C Di Grazia, T Lamparelli, F Galaverna, A Stasia, S Luchetti, S Geroldi & A Bacigalupo

  2. Clinica Ematologica, IRCSS San Martino, Genova, Italy

    R Grasso & N Colombo

Authors
  1. A Ghiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A M Raiola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Gualandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Dominietto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Varaldo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M T Van Lint
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Bregante
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Di Grazia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Lamparelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F Galaverna
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Stasia
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Luchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S Geroldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R Grasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. N Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A Bacigalupo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Bacigalupo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghiso, A., Raiola, A., Gualandi, F. et al. DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant 50, 56–61 (2015). https://doi.org/10.1038/bmt.2014.217

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.217

This article is cited by

Search

Advanced search

Quick links